Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — Technical state

The Closelooknet read

• Closelooknet score: 53 out of 100 (momentum 89 · quality 58 · valuation 30), as of 2026-11-03.
• Signal: Uptrend stack intact — Trades +6.6% vs the 50-day and +29.5% vs the 200-day average, 5.7% below the 52-week high and +103.2% off the 52-week low. Computed from daily closes. (as of 2026-11-02)
• Trend: Amneal Pharmaceuticals, Inc. Class A Common Stock trades 6.6% above its 50-day and 29.5% above its 200-day moving average. (as of 2026-11-02)

Amneal Pharmaceuticals develops, makes and distributes generic and specialty drugs, including injectables and biosimilars, from sites in the United States, India and Ireland. It groups its business into affordable generics, a specialty unit built around central nervous system and thyroid treatments such as Rytary and Unithroid, and a government-supply arm, AvKARE, that serves defence and veterans' health agencies.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the AMRX overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.